Ashley Lunkenheimer, RN Registered Nurse - Emergency Medicare: Not Enrolled in Medicare Practice Location: 2008 N Woodlawn Blvd, Derby, KS 67037 Phone: 316-640-0670 |
Nicole Ann Xanders-danler, Registered Nurse - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 425 N Baltimore Ave Ste 5, Derby, KS 67037 Phone: 316-260-7900 |
Shelly L Igo, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 9314 E Cherish Rd, Derby, KS 67037 Phone: 316-680-8898 |
Alexis Gomes, RN,BSN Registered Nurse - Case Management Medicare: Not Enrolled in Medicare Practice Location: 3300 N Emerson St, Derby, KS 67037 Phone: 316-685-2221 |
Kristen Grace Macaraeg Knowles, Registered Nurse - Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 958 N Lakeview Dr, Derby, KS 67037 Phone: 316-250-1669 |
Lauren Nichole Chavez, RN Registered Nurse - Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 5860 S 103rd St E, Derby, KS 67037 Phone: 316-393-7148 |
News Archive
EarlySense announced today that its EverOn Touch system has been cleared for marketing by the U.S. Food and Drug Administration. The FDA clearance covers several key additions to the traditional EverOn contact-free patient supervision system value proposition. For the first time, the EverOn system includes an online display that alerts medical staff regarding a patient's motion level and verifies patient turns as indicated by nurses. Identifying low patient movement and then turning patients methodically are key elements in the prevention of pressure ulcers, the most costly patient safety risk in U.S. hospitals.
Scientists at the Gladstone Institute of Neurological Disease and Stanford University have shown how key circuits in the brain control movement. The research, published in the journal Nature not only establishes the function of these circuits, but offers promise for treating movement related disorders, such as Parkinson's disease.
ETC-159, a made-in-Singapore anti-cancer drug that is currently in early phase clinical trials for use in a subset of colorectal and gynecological cancers, could also prevent some tumors from resisting therapies by blocking a key DNA repair mechanism, researchers from Duke-NUS Medical School and the Agency for Science, Technology and Research in Singapore reported in the journal EMBO Molecular Medicine.
Bayer HealthCare announced today that the company will present data on several of its investigational compounds at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.
Why does breast cancer develop and how come certain patients are resistant to established therapies? Researchers from the University of Basel have gained new insights into the molecular processes in breast tissue.
› Verified 7 days ago